CN103405751B - 一种具有细胞修复功能的组合物及其制备方法和应用 - Google Patents
一种具有细胞修复功能的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN103405751B CN103405751B CN201310369405.8A CN201310369405A CN103405751B CN 103405751 B CN103405751 B CN 103405751B CN 201310369405 A CN201310369405 A CN 201310369405A CN 103405751 B CN103405751 B CN 103405751B
- Authority
- CN
- China
- Prior art keywords
- visceral
- obtains
- tissue
- internal organs
- homogenate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000005779 cell damage Effects 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims abstract description 5
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims abstract description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 3
- 230000009279 non-visceral effect Effects 0.000 claims description 55
- 210000001519 tissue Anatomy 0.000 claims description 52
- 210000001835 viscera Anatomy 0.000 claims description 43
- 239000007788 liquid Substances 0.000 claims description 31
- 230000008439 repair process Effects 0.000 claims description 27
- 238000010257 thawing Methods 0.000 claims description 22
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 102000013275 Somatomedins Human genes 0.000 claims description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 208000037887 cell injury Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 230000002779 inactivation Effects 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 230000002232 neuromuscular Effects 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 108010019160 Pancreatin Proteins 0.000 claims description 3
- 210000000577 adipose tissue Anatomy 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 229940055695 pancreatin Drugs 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 51
- 206010052428 Wound Diseases 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 239000003102 growth factor Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 230000006870 function Effects 0.000 description 59
- 238000011282 treatment Methods 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 24
- 239000003814 drug Substances 0.000 description 16
- 230000006378 damage Effects 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000011010 flushing procedure Methods 0.000 description 12
- 230000035876 healing Effects 0.000 description 12
- 239000011550 stock solution Substances 0.000 description 12
- 238000011069 regeneration method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000002980 postoperative effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 238000010792 warming Methods 0.000 description 8
- 230000003387 muscular Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 229920001661 Chitosan Polymers 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012466 permeate Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 208000035965 Postoperative Complications Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 210000000589 cicatrix Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000009804 total hysterectomy Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010034238 Pelvic adhesions Diseases 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 101150015424 dmd gene Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 238000013123 lung function test Methods 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000009306 yunnan baiyao Substances 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 244000257039 Duranta repens Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035620 dolor Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
指标名称及单位 | 治疗组(20例) | 对照组(20例) |
术后褐色出血持续时间(平均天数) | 6.8 | 12.3 |
术后腹部疼痛感持续时间(平均天数) | 48.5 | 89.3 |
术后发生并发症(总例数) | 0 | 3 |
术后恢复工作时间(平均天数) | 55.6 | 98.7 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310369405.8A CN103405751B (zh) | 2013-08-22 | 2013-08-22 | 一种具有细胞修复功能的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310369405.8A CN103405751B (zh) | 2013-08-22 | 2013-08-22 | 一种具有细胞修复功能的组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103405751A CN103405751A (zh) | 2013-11-27 |
CN103405751B true CN103405751B (zh) | 2015-05-20 |
Family
ID=49598824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310369405.8A Active CN103405751B (zh) | 2013-08-22 | 2013-08-22 | 一种具有细胞修复功能的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103405751B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632653A (zh) * | 2017-01-09 | 2017-05-10 | 上海新肌生物科技有限公司 | 使受损细胞具有复活效果的复活素的培养方法 |
CN109331037B (zh) * | 2018-12-26 | 2023-04-07 | 珠海安肽生物医药技术开发有限公司 | 外用抑瘢凝胶组合物 |
CN109453104B (zh) * | 2018-12-26 | 2021-05-07 | 粤肽生物科技(珠海)有限公司 | 淡斑爽肤精华液及其制备工艺 |
CN109568652A (zh) * | 2018-12-26 | 2019-04-05 | 粤肽生物科技(珠海)有限公司 | 促进伤口快速愈合的敷料组合物 |
CN114099366B (zh) * | 2021-11-17 | 2023-06-20 | 珠海安肽生物医药技术开发有限公司 | 一种促进细胞能量代谢的无菌抗衰祛皱组合液及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002509855A (ja) * | 1997-10-16 | 2002-04-02 | ズー、デグアン | 皮膚、頭皮もしくは創傷への局所施用のための組成物及びその製造方法 |
US20080038234A1 (en) * | 2004-03-23 | 2008-02-14 | Shuji Hayashi | Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair |
CN1969039A (zh) * | 2004-06-11 | 2007-05-23 | 伯纳德·奥布赖恩显微外科研究院 | 组织材料和肌肉来源的基质 |
CN100441199C (zh) * | 2005-02-02 | 2008-12-10 | 多布瑞菲医药有限公司 | 一种脾提取物、其制备方法及其用途 |
CN103356707B (zh) * | 2005-03-31 | 2016-07-06 | 斯丹姆涅恩有限公司 | 制备用以治疗伤口或糖尿病性神经病引发的溃疡,或预防手术后疝形成的药物的方法 |
EP2801377B1 (en) * | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
CN102836429B (zh) * | 2011-06-22 | 2015-04-01 | 苏州万木春生物技术有限公司 | 修复受损组织的抗体靶向药物、给药方法及磁共振造影剂 |
-
2013
- 2013-08-22 CN CN201310369405.8A patent/CN103405751B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103405751A (zh) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ferrero et al. | Ultrasound-guided injection of platelet-rich plasma in chronic Achilles and patellar tendinopathy | |
Dai et al. | Negative regulation of PI3K/AKT/mTOR axis regulates fibroblast proliferation, apoptosis and autophagy play a vital role in triptolide-induced epidural fibrosis reduction | |
CN103405751B (zh) | 一种具有细胞修复功能的组合物及其制备方法和应用 | |
JP2022123073A (ja) | Efpの治療または低減方法 | |
TWI466675B (zh) | 用於抑制發炎之醫藥組合物 | |
Dallaudière et al. | Efficacy of intra-tendinous injection of platelet-rich plasma in treating tendinosis: comprehensive assessment of a rat model | |
CN109641013A (zh) | 包含凝血酶处理干细胞来源的外泌体的皮肤创伤的治疗用组合物 | |
Carleton et al. | Methacrylic acid-based hydrogels enhance skeletal muscle regeneration after volumetric muscle loss in mice | |
KR20190126894A (ko) | 치료법에서 사용하기 위한 보툴리눔 신경독소 | |
Xu et al. | Autocross-linked hyaluronic acid gel and adipose-derived mesenchymal stem cell composites for the treatment intrauterine adhesions | |
CN107951904B (zh) | 一种脂肪间充质干细胞药物及其制备方法和应用 | |
RU2433844C1 (ru) | Способ лечения дегенеративно-дистрофических заболеваний опорно-двигательного аппарата и посттравматических болевых синдромов | |
Hu et al. | Injectable hydrogel with selenium nanoparticles delivery for sustained glutathione peroxidase activation and enhanced osteoarthritis therapeutics | |
RU2292212C1 (ru) | Кондиционная среда, обладающая лечебным эффектом | |
US11826381B2 (en) | Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments | |
KR20150131864A (ko) | 어류의 정액 또는 정소로부터 분리된 디엔에이 단편 혼합물을 함유하는 회전근개 파열의 예방 또는 치료용 약학 조성물 | |
KR102312643B1 (ko) | 방광염을 치료하기 위해 저장 안정성이 증가된, 콘드로이틴 설페이트 (20 mg/ml), 히알루론산 (16 mg/ml) 및 포스페이트 버퍼 (ph 6.1 내지 7.9)를 함유하며 방광 점적 주입 조성물 | |
TWI787761B (zh) | 粒線體用於促進傷口修復及/或傷口癒合之用途 | |
CN104606667A (zh) | 重组牛碱性成纤维细胞生长因子凝胶 | |
CN108853081B (zh) | 穗花杉双黄酮在制备治疗鸡坏死性肠炎的药物中的用途 | |
CN110237091A (zh) | 一种可用于儿童的透明质酸修护生物膜 | |
CN104606177B (zh) | 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用 | |
KR102312625B1 (ko) | 방광염의 치료를 위해 증가된 저장 안정성을 갖고 콘드로이틴 설페이트 (4.5 mg/ml), 히알루론산 (16 mg/ml) 및 포스페이트 버퍼 (ph 6.1 내지 7.9)를 함유하는 방광 점적 주입 조성물 | |
RU2350366C1 (ru) | Способ лечения последствий травм суставов | |
Pereira et al. | Effects of intra-articular administration of hyaluronic acid or platelet-rich plasma as a complementary treatment to arthroscopy in horses with osteochondritis dissecans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170627 Address after: 5 building, B building, No. three, 8 Jin Hong Road, Tang Wan Town, Guangdong, Zhuhai, 519085 Patentee after: Zhuhai peptide Biological Medicine Technology Development Co Ltd Address before: 519085, Guangdong Province, Xiangzhou District, Zhuhai, Tang Town, Jinding, Jin Hong, No. three, No. 8, block B, 5 floor Patentee before: Zhao Xuan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181207 Address after: 519000 Commercial Service Center - 121 (Centralized Office Area) of Guangdong-Australia Cooperative TCM Science and Technology Industrial Park, No. 2522 Huandao North Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee after: Guangdong Peptide Biotechnology (Zhuhai) Co., Ltd. Address before: 519085 Building 5, 8B, Jinhong Third Road, Tangjiawan Town, Zhuhai City, Guangdong Province Patentee before: Zhuhai peptide Biological Medicine Technology Development Co Ltd |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200116 Address after: 519000 5th floor, building B, No. 8, Jinhong 3rd road, Tangjiawan Town, Zhuhai City, Guangdong Province Patentee after: Zhuhai peptide Biological Medicine Technology Development Co Ltd Address before: 519000 Commercial Service Center - 121 (Centralized Office Area) of Guangdong-Australia Cooperative TCM Science and Technology Industrial Park, No. 2522 Huandao North Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee before: Guangdong Peptide Biotechnology (Zhuhai) Co., Ltd. |
|
TR01 | Transfer of patent right |